The Efficacy of a US-Based Medicine Recycling Program Delivering Antiretroviral Drugs Worldwide

Abstract

Since 1996, AID FOR AIDS International (AFAI) has collected unused antiretroviral drugs (ART) and ``recycled'' these medications to over 600 people living with human immunodeficiency virus/AIDS abroad under its AIDS Treatment Access Program. The investigators evaluated AIDS Treatment Access Program's efficacy using immunologic and virologic outcomes. Of the 404 eligible clients who had baseline and follow-up CD4 counts, mean baseline versus most recent measure was 230 + 222 cells/mm³ versus 372 + 256 cells/mm³ (P < .01). Of the 216 eligible clients who had baseline (>400 copies/mL) and follow-up viral loads, 62% (134/ 216) had undetectable viral loads (<400 copies/mL) at their most recent measure. Median enrollment time in the recycling program was 3.1 years (range: 6 months to 9.5 years). AFAI's medication recycling program is efficacious in reaching and improving the clinical outcomes of people living with HIV/AIDS (PLWHA). Such programs should be considered a viable option among scale-up programs until governments provide universal access of ART to PLWHA.

Keywords

antiretroviral therapy health services accessibility/economics poverty areas program evaluation

References

Unaids / World Health Organization. 2008 Report on the Global AIDS Epidemic. Annex l: HIV and AIDS estimates and data, 2007 and 2001. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. Accessed August 5, 2008.

World Health Organization. Treating 3 million by 2005: making it happen. The WHO strategy. Available at: http://www.who.int/3by5/publications/documents/isbn9241591129/en/. Accessed August 5, 2008.

von Schoen Angerer T. , Wilson D. , Ford N. , Kasper T. Access and activism: the ethics of providing antiretroviral therapy in developing countries. AIDS. 2001;15(suppl 5): S81-S90.

Hardon A. , Davey S. , Gerrits T. , et al. From access to adherence: the challenges of antiretroviral treatment . Geneva: World Health Organization Press; 2006.

Accelerating access initiative: progress report. World Health Organization Web site. Available at: http://www.who.int/hiv/pub/prev_care/aai/en/. Accessed August 5, 2008.

Boerma JT , Stanecki KA , Newell ML , et al. Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ. 2006;84:145-150.

World Health Organization. ``3 by 5'' Progress Report, June 2005: Progress on Global Access to HIV Antiretroviral Therapy . Available at: http://www.who.int/3by5/publications/progressreport/en/index.html . Accessed August 5, 2008.

Bartlett JA , Fath MJ , Demasi R. , et al. An updated systematic overview of triple combination therapy in antiretroviral-naïve HIV-infected adults. AIDS. 2006;20: 2051-2064.

Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Recomm Rep. 1998 ;47: 42-82.

10.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Available at: http://www.who.int/entity/hiv/pub/guidelines/artadultguidelines.pdf. Accessed August 5, 2008.

11.

Farmer P. , Leandre F. , Mukherjee JS , et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet. 2001;358:404-409.

12.

Koenig SP , Leandre F. , Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. 2004;18(suppl 3): S21-S25.

13.

Coetzee D. , Hildebrand K. , Boulle A. , et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18: 887-895.

14.

Kabugo C. , Bahendeka S. , Mwebaze R. , et al. Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses . J Acquir Immune Defic Syndr. 2005;38:578-583.

15.

Orrell C. , Bangsberg DR , Badri M. , Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa . AIDS. 2003;17:1369-1375.